(Q38262255)

1 September 2017

1 reference

title

Overcoming tumor-mediated immunosuppression (English)

1 reference

Michael von Bergwelt-Baildon

1 September 2017

1 reference

6

Alexander Shimabukuro-Vornhagen

Michael von Bergwelt-Baildon

0 references

3

Alexander Shimabukuro-Vornhagen

0 references

Sebastian Theurich

2

Sebastian Theurich

0 references

Udo Holtick

4

Udo Holtick

0 references

author name string

Hans Anton Schlößer

1

1 reference

PubMed ID

25341119

1 September 2017

Dirk Ludger Stippel

5

1 reference

1 September 2017

1 January 2014

1 reference

1 September 2017

1 reference

1 September 2017

6

1 reference

1 September 2017

9

1 reference

1 September 2017

973-988

1 reference

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 September 2017

1 reference

Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma

21 January 2018

1 reference

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment

21 January 2018

1 reference

Immunotherapeutic strategies for high-risk bladder cancer

21 January 2018

1 reference

Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.

21 January 2018

1 reference

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy

21 January 2018

1 reference

Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma

21 January 2018

1 reference

Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis

21 January 2018

1 reference

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

Immunotherapy for prostate cancer: biology and therapeutic approaches

21 January 2018

1 reference

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

Exploiting the curative potential of adoptive T-cell therapy for cancer

21 January 2018

1 reference

GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia

21 January 2018

1 reference

Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation.

21 January 2018

1 reference

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

21 January 2018

1 reference

Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy

21 January 2018

1 reference

Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.

21 January 2018

1 reference

Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.

21 January 2018

1 reference

Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells

21 January 2018

1 reference

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

21 January 2018

1 reference

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

Bispecific T-cell engaging antibodies for cancer therapy

21 January 2018

1 reference

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.

21 January 2018

1 reference

New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting

21 January 2018

1 reference

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

21 January 2018

1 reference

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody

21 January 2018

1 reference

A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells

21 January 2018

1 reference

Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.

21 January 2018

1 reference

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer

21 January 2018

1 reference

Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer

21 January 2018

1 reference

What are regulatory T cells (Treg) regulating in cancer and why?

21 January 2018

1 reference

Toll-like receptor signalling on Tregs: to suppress or not to suppress?

21 January 2018

1 reference

Targeting regulatory T cells

21 January 2018

1 reference

Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy

21 January 2018

1 reference

Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma

21 January 2018

1 reference

Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth.

21 January 2018

1 reference

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients

21 January 2018

1 reference

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

21 January 2018

1 reference

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells

21 January 2018

1 reference

ENTPD1/CD39 is a promising therapeutic target in oncology

21 January 2018

1 reference

Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression

21 January 2018

1 reference

Control of immunity by the TNFR-related molecule OX40 (CD134)

21 January 2018

1 reference

Science gone translational: the OX40 agonist story

21 January 2018

1 reference

A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.

21 January 2018

1 reference

OX40 is a potent immune-stimulating target in late-stage cancer patients

21 January 2018

1 reference

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

21 January 2018

1 reference

Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells.

21 January 2018

1 reference

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy

21 January 2018

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

21 January 2018

1 reference

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

21 January 2018

1 reference

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

21 January 2018

1 reference

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues

21 January 2018

1 reference

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

21 January 2018

1 reference

Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells

21 January 2018

1 reference

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

21 January 2018

1 reference

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer

21 January 2018

1 reference

CD20+ B cells: the other tumor-infiltrating lymphocytes

21 January 2018

1 reference

Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia

21 January 2018

1 reference

B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation.

21 January 2018

1 reference

B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice

21 January 2018

1 reference

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.

21 January 2018

1 reference

B-cell-derived lymphotoxin promotes castration-resistant prostate cancer

21 January 2018

1 reference

CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation

21 January 2018

1 reference

B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma.

21 January 2018

1 reference

Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells

21 January 2018

1 reference

CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.

21 January 2018

1 reference

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

21 January 2018

1 reference

FcRgamma activation regulates inflammation-associated squamous carcinogenesis.

21 January 2018

1 reference

Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers

21 January 2018

1 reference

Multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies

21 January 2018

1 reference

Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells

21 January 2018

1 reference

The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells

21 January 2018

1 reference

Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer

21 January 2018

1 reference

Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients

21 January 2018

1 reference

Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma

21 January 2018

1 reference

Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.

21 January 2018

1 reference

The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment

21 January 2018

1 reference

Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment

21 January 2018

1 reference

Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation

21 January 2018

1 reference

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

21 January 2018

1 reference

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques.

21 January 2018

1 reference

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

21 January 2018

1 reference

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

21 January 2018

1 reference

Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma

21 January 2018

1 reference

Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma

21 January 2018

1 reference

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

21 January 2018

1 reference

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

21 January 2018

1 reference

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

21 January 2018

1 reference

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

21 January 2018

1 reference

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer.

21 January 2018

1 reference

CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction

21 January 2018

1 reference

Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives

21 January 2018

1 reference

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

21 January 2018

1 reference

Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma

21 January 2018

1 reference

IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival

21 January 2018

1 reference

Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.

21 January 2018

1 reference

Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer.

21 January 2018

1 reference

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

21 January 2018

1 reference

Cytokine patterns in patients with cancer: a systematic review.

21 January 2018

1 reference

Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients

21 January 2018

1 reference

Targeting the transforming growth factor-beta signaling pathway in human cancer

21 January 2018

1 reference

Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes

21 January 2018

1 reference

Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer.

21 January 2018

1 reference

Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer

21 January 2018

1 reference

Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?

21 January 2018

1 reference

HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma

21 January 2018

1 reference

TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis

21 January 2018

1 reference

The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer

21 January 2018

1 reference

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

21 January 2018

1 reference

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

21 January 2018

1 reference

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

21 January 2018

1 reference

IL-18 Induces PD-1-Dependent Immunosuppression in Cancer

21 January 2018

1 reference

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro

21 January 2018

1 reference

Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

21 January 2018

1 reference

A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin C as a Compatible Prognostic Marker in Human Solid Tumors

21 January 2018

1 reference

Immunotherapy for advanced renal cell cancer

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425.PUB2

Identifiers

DOI

10.2217/IMT.14.58

1 reference

release_yqj64pd55ng2zggd2fuajeqsce

1 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yqj64pd55ng2zggd2fuajeqsce

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

25341119

1 reference

PubMed ID

25341119